Table 1.

ER and PR status from different data sources among women ages 35 to 64 y with invasive breast cancer in the Women's CARE Study

Receptor status from a centralized pathology laboratory	Receptor status from SEER registries
ER status	ER−	ER+
ER−	316 (92%)	122 (17%)
ER+	28 (8%)	582 (83%)
κ (95% CI)	0.70 (0.65−0.74)
PR status	PR−	PR+
PR−	296 (83%)	121 (21%)
PR+	60 (17%)	449 (79%)
κ (95% CI)	0.60 (0.55–0.65)
Joint ER/PR status	ER−/PR−	ER+/PR+	ER+/PR−	ER−/PR+
ER−/PR−	240 (90%)	48 (9%)	18 (20%)	36 (69%)
ER+/PR+	8 (3%)	392 (76%)	38 (43%)	8 (15%)
ER+/PR−	8 (3%)	35 (7%)	29 (33%)	2 (4%)
ER−/PR+	10 (4%)	38 (8%)	3 (3%)	6 (12%)
Overall κ (95% CI)	0.55 (0.51–0.59)
ER−/PR− κ (95% CI)	0.69 (0.64–0.74)
ER+/PR+ κ (95% CI)	0.62 (0.57–0.67)
ER+/PR− κ (95% CI)	0.30 (0.20–0.40)
ER−/PR+ κ (95% CI)	0.05 (−0.03 to 0.14)